31 DecSource: HemoBioTech.

Times Times concludes In the long run, full coverage should in the direction towards the reform of the health system increase increase quality, deliver cost-effective care. .. Source: HemoBioTech, Massachusetts Health Insurance Law Could be a model for the United States, editorial states, The groundbreaking Massachusetts looks program to health insurance for all citizens , more and more successful with each passing month, which suggests that the plan could be a model for the universal has become health insurance for other states or the nation, a New York Times editorial. According to the Times, the health insurance legislation riders reasonable decrease in the number of has , those that hospital emergency rooms and community health centers use for the routine care they showed not pay for them.

HemoTech was suffering successfully in a first clinical trial for the treatment of children with sickle cell disease apparent side effects apparent side effects. HemoTech stabilizes a cell factor called HIF-1 alpha, the induction of erythropoietin, which leads to increase the production of new red blood cells stimulated. HemoTech addresses a multi-billion dollar market for the treatment of acute blood loss and anemia with the advantage of fewer side effects and the ability to deliver oxygen in acute situations, said Dr.In addition the entity ongoing clinical studies and his drug candidates Augment and Augment An injectable in several Orthopaedic bone healing indications including the treat of foot and ankle mergers and of the stimulation to the healing of fractures of arm. The company is far been authorized product and of lead product candidates any combination recombinant protein therapeutics based on with tissue specific scaffolds is active to stimulate tissues healing and regeneration. GEM 21 is registered trademark of Luitpold Pharmaceuticals , which owns now and this product.. About BioMimetic TherapeuticsBioMimetic Therapeutics, developed and marketed bio active recombinant protein – Equipment combinations items for the treatment of musculoskeletal injuries and diseases, including orthopedic, spine and Sports Nutrition application.

– Strong speeding of entry in fourth quarter enabled which completion of enrollment in December, said Dr. Samuel Lynchburg, President and CEO BioMimetic Therapeutics. We are gratified of the surgeons commitment and confidence, that spring results we are expecting to be able to assess the clinical data to submit to the FDA during the fourth quarter of this year as the final element to our modular PMA tabling. The other two sections of the PMA, which pre-clinical and the quality / production sections brought in the schedule this spring, percent percent of platelet derived the main parameters of radiological fusion is evaluated to be done. Another important issue, the undertaking also announced today that the United States Patent Office issued Pat having to the ID 7 678, entitled Platelet-Derived Growth Factor composition and methods of their use.